Viatris Inc. (VTRS) stock plummeted 7.21% in pre-market trading on Thursday, following the company's release of disappointing fourth-quarter 2024 financial results.
The pharmaceutical giant reported adjusted earnings per share of $0.54, missing analysts' consensus estimate of $0.57 by 5.26%. Additionally, Viatris' quarterly revenue of $3.52 billion fell short of the expected $3.61 billion, marking an 8.13% year-over-year decline.
As a global healthcare company focused on providing access to high-quality medicines worldwide, Viatris' ability to meet or exceed earnings expectations is crucial for investor confidence. The missed targets on both earnings and revenue suggest challenges in executing the company's growth strategy, which likely weighed heavily on the stock's performance in early trading.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。